Is Nuvectis Pharma, Inc. (NVCT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 13.3% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 13.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 99.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 13.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 99.8% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -188.0% | |
| Return on Assets (ROA) | -68.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$16M |
| Free Cash Flow | -$16M |
| Current Ratio | 2.4 |
| Total Assets | $32M |
Price & Trading
| Last Close | $7.81 |
| 50-Day MA | $8.62 |
| 200-Day MA | $7.35 |
| Avg Volume | 63K |
| Beta | -0.3 |
|
52-Week Range
$5.55
| |
About Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Nuvectis Pharma, Inc. (NVCT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Nuvectis Pharma, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Nuvectis Pharma, Inc.'s debt ratio?
Nuvectis Pharma, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Nuvectis Pharma, Inc.'s key financial metrics?
Nuvectis Pharma, Inc. has a market capitalization of $198M. Return on equity stands at -188.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.